The FDA has accepted Genentech’s supplemental Biologics License Application (sBLA) for its innovator bevacizumab (Avastin) in combination with carboplatin and paclitaxel chemotherapy, followed by Avastin alone, for the front-line treatment of women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The FDA has accepted Genentech’s supplemental Biologics License Application (sBLA) for its innovator bevacizumab (Avastin) in combination with carboplatin and paclitaxel chemotherapy, followed by Avastin alone, for the front-line treatment of women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Avastin, an angiogenesis inhibitor, is currently approved for treatment of 2 different forms of advanced cancer that recurred after platinum-based chemotherapy (non-squamous non—small cell lung cancer, carcinoma of the colon or rectum, and renal cell carcinoma). The FDA is expected to decide on whether to approve the new indication for Avastin by June 25, 2018.
This sBLA for Avastin, in the combination and order of treatment as specified, is based on data from the pivotal phase 3 GOG-0218 trial, which was conducted by the Gynecologic Oncology Group and published in The New England Journal of Medicine. GOG-0218 was a multicenter, randomized, double-blind, placebo-controlled phase 3 study in 1873 women with previously untreated advanced epithelial ovarian, primary peritoneal, or fallopian tube carcinoma who already had surgery to remove as much of the tumor as possible. Study participants were randomized to 1 of 3 treatment arms:
Women who received Avastin in combination with chemotherapy, and continued use of Avastin alone for a duration of 22 cycles, lived the longest without disease progression, with a median progression-free survival of 18.2 months compared with 12.0 months in women who received chemotherapy alone (hazard ratio, 0.64; 95% confidence interval, 0.54-0.77; P < .001).
Secondary endpoints of the study included overall survival and objective response rate. Adverse events were consistent with those seen in previous trials of Avastin across tumor types for approved indications, the company said.
The sBLA seeking the new indication follows closely on the heels of the FDA’s approval of Amgen’s bevacizumab biosimilar, ABP 215 (Mvasi), the first biosimilar of Avastin approved for use in the United States. Amgen, seeking to launch its product, is currently engaged in a lawsuit against Genentech in a California district court. Amgen seeks a judgment that its biosimilar has not infringed on 27 patents covering the reference bevacizumab. When Amgen eventually brings Mvasi to the US marketplace, the biosimilar will compete for a share of substantial bevacizumab sales; Avastin was responsible for $6.75 billion in global sales for Genentech in 2016.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.